Veru (NASDAQ:VERU – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01, Zacks reports. Veru had a negative net margin of 223.85% and a negative return on equity of 92.88%.
Veru Price Performance
Shares of VERU stock opened at $0.53 on Friday. The company’s 50-day moving average is $0.72 and its 200 day moving average is $0.77. Veru has a one year low of $0.37 and a one year high of $1.92.
Wall Street Analysts Forecast Growth
VERU has been the topic of several research reports. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of Veru in a research report on Thursday, January 2nd. Oppenheimer reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Veru in a research note on Tuesday, November 5th.
About Veru
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Further Reading
- Five stocks we like better than Veru
- Growth Stocks: What They Are, What They Are Not
- Cisco Roars Back: Is the Tech Giant Reborn?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Albemarle’s Earnings Are In—Is the Stock a Buy Now?
- How to Invest in Insurance Companies: A Guide
- Forget Tesla: 3 Stocks to Ride the Elon Musk Effect
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.
